Given the limited evidence that sPD-L1 may be a biomarker to predict the response to immunotherapy in gliomas, our study was performed to evaluate plasma concentrations of sPD-L1 before and after RT in glioma patients and to investigate the relationship of sPD-L1 levels with clinical outcomes. The gene discussed is SPDL1; the disease is glioma.